The Food and Drug Administration’s approval on Friday of AstraZeneca’s Lynparza as a treatment for some people with early-stage breast cancer could bring in $1.5 billion in annual revenue for the company. U.S.-listed shares of AstraZeneca were up 1.5% in trading on Monday. SVB Leerink analyst Andrew Berens told investors in a note on Monday that he expects rapid adoption of the therapy among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer who have previously received treatment. Lynparza is already approved as a treatment for ovarian cancer; it brought in $2.7 billion in revenue in 2022. Berens expects the drug to generate $9.7 billion in sales by 2028 when taking into account the breast-cancer approval and positive clinical data among prostate-cancer patients. AstraZeneca’s stock is up 5.1% this year, while the S&P 500 has declined 11.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
